http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2103901-A5
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2603-24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08F8-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C41-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C53-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C51-363 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C57-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D205-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G77-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C43-225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C17-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C271-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C43-225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D205-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D223-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08F8-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C53-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C209-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-363 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C39-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C41-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C57-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G69-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G77-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C23-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G77-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C17-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F7-12 |
| filingDate | 1971-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1972-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1972-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | FR-2103901-A5 |
| abstract | 1353519 Fluorination of organic compounds MERCK & CO Inc 26 July 1971 [3 Aug 1970 18 June 1971] 34887/71 Heading C2C [Also in Division C3] Substitutive fluorination of an organic compound containing at least one replaceable hydrogen atom attached to a carbon atom is effected by contacting the organic compound in the liquid or solid state with a C 1-5 fluoroxyperfluoroalkane or fluoroxypentafluorosulphur in the presence of a free-radical initiator, e.g. light, ionizing radiation or a chemical chain initiator, such as an azo compound, e.g. azo-bis-isobutyronitrile. The substrate is preferably dissolved in a solvent inert to the fluorination reaction, e.g. fluorotrichloromethane or similar halogenated alkane or a strong acid such as liquid HF, fluorosulphonic acid, trifluoroacetic acid or sulphuric acid. Substrates include mono- or polynuclear aromatic or alicyclic compounds, alkanes, alkenes, amino acids, fatty acids or their amides and heterocyclic compounds. Many specific examples are given including the preparation of 3-fluoro-D-alanine, 3-fluoro-L-azetidine-2-carboxylic acid, 3- and 4-fluoro-1-aminoadamantane, difluoro-#-caprolactam acid trifluoro-#- caprolactam. Preparation of intermediates is described as follows: 2-Methylindanone is reacted with cyanacetic acid to form 2-methylinden-3-acetic acid which is reacted with p-methylthiobenzaldehyde to yield 2-methyl-1-(p-methylthiobenzylidene)-inden-3-acetic acid; oxidation with sodium periodate gives 2-methyl-1-(p-methyl sulphinylbenzylidene)inden-3-acetic acid; a Grignard reagent formed from 4-bromobibenzyl was reacted with acetone to form 4-(2-phenethyl)-phenylpropanol-2 which was reacted with NaCN in glacial acetic acid to form α,α-dimethyl-N- formyl-4-phenethylbenzylamine; the latter was treated with HCl to form 4-(2-phenethyl)-α,α- dimethylbenzylamine. HCl. 5 - Fluoro - 2 - methyl - 1 - (p - methylsulphinylbenzylidene)-inden-3-acetic acid has utility as an anti-inflammatory, analgesic and antipyretic agent and can be administered orally, rectally, parenterally or topically. 4-(2-Phenyl- 1,1,2,2 - tetrafluoroethyl) - α,α - dimethylbenzylamine is useful as an antiarrythmic agent for administration orally or parenterally in compositions containing conventional pharmaceutical carriers or excipients. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0558043-A1 |
| priorityDate | 1970-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.